Capula Management’s Moderna MRNA Stock Holding History

Capula Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.54M	Buy	+50,000	New	+$2.33M	0.02%	214
2025 Q3	–	Sell	-2,400	Closed	-$66.2K	–	863
2025 Q2	$66.2K	Buy	+2,400	New	+$63.2K	﹤0.01%	564
2024 Q3	–	Sell	-1,400	Closed	-$166K	–	585
2024 Q2	$166K	Sell	1,400 -2,100	-60%	-$266K	﹤0.01%	398
2024 Q1	$373K	Buy	+3,500	New	+$353K	0.01%	299
2023 Q3	–	Sell	-21,900	Closed	-$2.66M	–	611
2023 Q2	$2.66M	Sell	21,900 -33,800	-61%	-$4.51M	0.06%	127
2023 Q1	$8.55M	Buy	+55,700	New	+$9.19M	0.1%	171
2022 Q4	–	Sell	-14,700	Closed	-$1.74M	–	844
2022 Q3	$1.74M	Buy	+14,700	New	+$2.23M	0.02%	375
2021 Q4	–	Sell	-3,600	Closed	-$1.39M	–	574
2021 Q3	$1.39M	Hold	3,600	–	–	0.02%	464
2021 Q2	$846K	Buy	+3,600	New	+$643K	0.01%	386

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capula Management's MRNA Position: Q1 2026 in Review

Capula Management opened a new position in Moderna (MRNA) in Q1 2026: 14,500 shares worth $737K. The stake represents 0.01% of the portfolio and ranks #423 among its holdings. This is a return to the name: Capula Management previously reported a position in MRNA as recently as Q2 2025.

Capula Management first reported a position in MRNA in Q2 2021 and has held it in 10 quarters since. The position peaked at $962K in Q3 2022. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Capula Management held 14,500 shares of Moderna worth $737K as of Q1 2026.
Moderna was a new Capula Management position in Q1 2026.
Moderna made up 0.01% of Capula Management's portfolio in Q1 2026, its #423 holding.
Capula Management first reported a position in Moderna in Q2 2021 and has held it in 10 quarters since.
Capula Management's Moderna position peaked at $962K in Q3 2022.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Capula Management's 13F filing for Q1 2026, filed 14 May 2026.